In SLOs, small soluble antigens (such as low-molecular-mass toxins) can diffuse through small pores in the subcapsular sinus and activate follicular B cells. However, as the subcapsular sinus and ...

A Phase I study included 13 patients with a variety of relapsed B-cell NHL (five follicular, three mantle cell, three DLBCL, two chronic lymphocytic leukemia/small-cell lymphoma [CLL/SLL]).

Ann LaCasce, MD, MMSc, delved into some of the most recent advances in the lymphoma space, exploring how these new therapies ...

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Kymriah was cleared by the FDA for the follicular lymphoma use last year as well, a little after Yescarta, adding to its earlier approvals for diffuse large B-cell lymphoma (DLBCL) and acute ...

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...